Literature DB >> 11515849

Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease.

I C Lawrance1, L Maxwell, W Doe.   

Abstract

BACKGROUND AND AIMS: Fibrosis is a major complication of inflammatory bowel disease (IBD), which may be mediated by the intestinal fibroblast. Our aim was to isolate and characterize mucosal fibroblasts from histologically normal intestine (control), ulcerative colitis (UC), inflamed Crohn's disease (CD), and fibrosed CD intestine.
METHODS: Fibroblasts were characterized by light and electron microscopy and immunohistochemistry. Fibroblast collagen secretion and proliferation were determined by 3H-proline and 3H-thymidine incorporation, and the effects of exposure to interleukin (IL)-1beta, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF)-beta1, insulin-like growth factor (IGF)-1, and macrophage colony stimulating factor (M-CSF) were determined.
RESULTS: No difference in doubling time was observed between the fibroblast populations from UC and CD intestine. All proliferated faster than fibroblasts from control intestine. Collagen secretion from IBD fibroblasts, independent of type, was increased compared with control fibroblasts and PDGF, bFGF, and TGF-beta1-induced collagen secretion from IBD fibroblasts.
CONCLUSIONS: These results suggest the presence of an activated subpopulation of fibroblasts in both UC and CD tissue irrespective of the presence of tissue fibrosis or disease type.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11515849     DOI: 10.1097/00054725-200108000-00008

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  38 in total

1.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

2.  Altered expression of type I insulin-like growth factor receptor in Crohn's disease.

Authors:  F El Yafi; R Winkler; P Delvenne; N Boussif; J Belaiche; E Louis
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

Review 3.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

4.  Fibrocytes, inflammation, and fibrosis in Crohn's disease: another piece of the puzzle.

Authors:  D Sorrentino
Journal:  Dig Dis Sci       Date:  2014-04       Impact factor: 3.199

Review 5.  Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis.

Authors:  Florian Rieder; Piero Biancani; Karen Harnett; Lisa Yerian; Gary W Falk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-18       Impact factor: 4.052

Review 6.  Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease.

Authors:  Florian Rieder; Sean Kessler; Miquel Sans; Claudio Fiocchi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-08-09       Impact factor: 4.052

Review 7.  Role of Rho kinase signal pathway in inflammatory bowel disease.

Authors:  Yuan Huang; Shiyu Xiao; Quanhang Jiang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

8.  Prostaglandin E₂ and polyenylphosphatidylcholine protect against intestinal fibrosis and regulate myofibroblast function.

Authors:  Angela C Baird; Frances Lloyd; Ian C Lawrance
Journal:  Dig Dis Sci       Date:  2015-01-29       Impact factor: 3.199

Review 9.  Crohn's disease complicated by strictures: a systematic review.

Authors:  Florian Rieder; Ellen M Zimmermann; Feza H Remzi; William J Sandborn
Journal:  Gut       Date:  2013-04-26       Impact factor: 23.059

10.  High expression of HSP47 in ulcerative colitis-associated carcinomas: proteomic approach.

Authors:  K Araki; T Mikami; T Yoshida; M Kikuchi; Y Sato; M Oh-ishi; Y Kodera; T Maeda; I Okayasu
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.